Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...

Connecticut passed a new law last week in an effort to lower its spending on weight-loss drugs for its state insurance ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

By Sukriti Gupta, Sanchayaita Roy and Twesha Dikshit (Reuters) -European shares ended lower on Tuesday, dragged down by heavyweight financial and healthcare stocks as investors awaited news on a ...

A pharmacist holds boxes of Ozempic, a semaglutide injection drug made by Novo Nordisk, in Provo, Utah, on March 29, 2023.

New Report Covers PolyPid's Latest Developments; After Blockbuster Phase 3 Results in Surgical Infection Prevention, Could This Israeli Innovator Become Big Pharma’s Most Coveted Acquisition ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

Adventurous speculators interested in a quick-strike opportunity may want to set their sights on Novo Nordisk (NYSE: NVO ).

Lotte Bjerre Knudsen, Chief Scientific Adviser for Research at Danish pharma giant Novo Nordisk, speaks about GLP-1-based ...

If you have $1,000 to invest right now, you may be wondering where to get started. You could buy stocks that are flying high ...